BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20373461)

  • 1. Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria.
    De Giorgio M; Vezzoli S; Cohen E; Armellini E; Lucà MG; Verga G; Pinelli D; Nani R; Valsecchi MG; Antolini L; Colledan M; Fagiuoli S; Strazzabosco M
    Liver Transpl; 2010 Apr; 16(4):503-12. PubMed ID: 20373461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement?
    Roayaie K; Feng S
    Liver Transpl; 2007 Nov; 13(11 Suppl 2):S36-43. PubMed ID: 17969067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
    Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
    Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data.
    Pelletier SJ; Fu S; Thyagarajan V; Romero-Marrero C; Batheja MJ; Punch JD; Magee JC; Lok AS; Fontana RJ; Marrero JA
    Liver Transpl; 2009 Aug; 15(8):859-68. PubMed ID: 19642139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy.
    Huo TI; Wu JC; Lin HC; Lee FY; Hou MC; Huang YH; Lee PC; Chang FY; Lee SD
    Liver Transpl; 2004 Dec; 10(12):1507-13. PubMed ID: 15558587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma.
    Otto G; Herber S; Heise M; Lohse AW; Mönch C; Bittinger F; Hoppe-Lotichius M; Schuchmann M; Victor A; Pitton M
    Liver Transpl; 2006 Aug; 12(8):1260-7. PubMed ID: 16826556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma.
    Hu RH; Ho MC; Wu YM; Yu SC; Lee PH
    Clin Transplant; 2005 Apr; 19(2):175-80. PubMed ID: 15740552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.
    Ioannou GN; Perkins JD; Carithers RL
    Gastroenterology; 2008 May; 134(5):1342-51. PubMed ID: 18471511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria.
    D'Amico F; Schwartz M; Vitale A; Tabrizian P; Roayaie S; Thung S; Guido M; del Rio Martin J; Schiano T; Cillo U
    Liver Transpl; 2009 Oct; 15(10):1278-87. PubMed ID: 19790142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation.
    Lao OB; Weissman J; Perkins JD
    Clin Transplant; 2009; 23(6):874-81. PubMed ID: 19453644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy.
    Cucchetti A; Cescon M; Bigonzi E; Piscaglia F; Golfieri R; Ercolani G; Cristina Morelli M; Ravaioli M; Daniele Pinna A
    Liver Transpl; 2011 Nov; 17(11):1344-54. PubMed ID: 21837731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver transplantation for hepatocellular carcinoma in patients beyond the Milan but within the UCSF criteria.
    Sotiropoulos GC; Molmenti EP; Omar OS; Bockhorn M; Brokalaki EI; Lang H; Frilling A; Broelsch CE; Malagó M
    Eur J Med Res; 2006 Nov; 11(11):467-70. PubMed ID: 17182358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.
    Chapman WC; Majella Doyle MB; Stuart JE; Vachharajani N; Crippin JS; Anderson CD; Lowell JA; Shenoy S; Darcy MD; Brown DB
    Ann Surg; 2008 Oct; 248(4):617-25. PubMed ID: 18936575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma.
    Dhanasekaran R; Khanna V; Kooby DA; Spivey JR; Parekh S; Knechtle SJ; Carew JD; Kauh JS; Kim HS
    J Vasc Interv Radiol; 2010 Aug; 21(8):1197-204; quiz 204. PubMed ID: 20656222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.
    Facciuto ME; Koneru B; Rocca JP; Wolf DC; Kim-Schluger L; Visintainer P; Klein KM; Chun H; Marvin M; Rozenblit G; Rodriguez-Davalos M; Sheiner PA
    Ann Surg Oncol; 2008 May; 15(5):1383-91. PubMed ID: 18320284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study.
    Vitale A; Morales RR; Zanus G; Farinati F; Burra P; Angeli P; Frigo AC; Del Poggio P; Rapaccini G; Di Nolfo MA; Benvegnù L; Zoli M; Borzio F; Giannini EG; Caturelli E; Chiaramonte M; Trevisani F; Cillo U;
    Lancet Oncol; 2011 Jul; 12(7):654-62. PubMed ID: 21684210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era.
    Porrett PM; Peterman H; Rosen M; Sonnad S; Soulen M; Markmann JF; Shaked A; Furth E; Reddy KR; Olthoff K
    Liver Transpl; 2006 Apr; 12(4):665-73. PubMed ID: 16482577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond the Milan criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation?
    De Carlis L; Di Sandro S; Giacomoni A; Slim A; Lauterio A; Mangoni I; Mihaylov P; Pirotta V; Aseni P; Rampoldi A
    J Clin Gastroenterol; 2012 Jan; 46(1):78-86. PubMed ID: 21897282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.
    Shah SA; Cleary SP; Wei AC; Yang I; Taylor BR; Hemming AW; Langer B; Grant DR; Greig PD; Gallinger S
    Surgery; 2007 Mar; 141(3):330-9. PubMed ID: 17349844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis.
    Bozorgzadeh A; Orloff M; Abt P; Tsoulfas G; Younan D; Kashyap R; Jain A; Mantry P; Maliakkal B; Khorana A; Schwartz S
    Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.